Close X
Friday, November 22, 2024
ADVT 
Health

News of potential COVID vaccine 'encouraging': PM

Darpan News Desk The Canadian Press, 09 Nov, 2020 06:07 PM
  • News of potential COVID vaccine 'encouraging': PM

Prime Minister Justin Trudeau says he hopes to see COVID-19 vaccines roll out in Canada early next year, but warns that won't bring an immediate resolution to the pandemic currently seeing a resurgence in several provinces.

The prime minister says news from Pfizer today that one of its vaccine candidates appears very effective in clinical trials is "very encouraging" but won't help anyone who catches the virus in the meantime.

Speaking in Ottawa, Trudeau said other vaccine candidates have also appeared to progress well.

His comments come after a weekend that saw the two provinces hardest hit by the pandemic report record-breaking daily case counts.

Quebec reported 1,397 new cases on Sunday and Ontario reported 1,328, nearly 200 more than the record it had set the previous day.

The number of new infections stayed above 1,000 in Ontario on Monday, with 1,242 reported.

Canada has bought the rights to 20 million doses of Pfizer's vaccine, if it proves effective and Health Canada approves it for use here, and Trudeau said the government would purchase more if the initial round goes well.

The company said in a news release that early results from a large-scale trial show its vaccine is 90 per cent effective at combating the virus.

Tedros Adhanom Ghebreyesus with the World Health Organization also reacted to the good news via Twitter.

"We hope to see vaccines landing in the early next year but between now and then it's really really important that we double down on our efforts," Trudeau said.

"We need to make sure we are controlling the spread of COVID-19 in the coming months so that when vaccines get here we will be able to act quickly to protect all Canadians."

MORE Health ARTICLES

Health panel may open lung cancer screening to more smokers

Health panel may open lung cancer screening to more smokers
A U.S. health panel wants to widen the number of Americans offered yearly scans for lung cancer by opening the screening to less-heavy smokers.

Health panel may open lung cancer screening to more smokers

Health care workers at risk of PTSD from COVID: guide

Health care workers at risk of PTSD from COVID: guide
The Centre of Excellence on Post-Traumatic Stress Disorder says health-care workers on the front lines of the COVID-19 pandemic are susceptible to severe stress that could cause long-term psychological damage.

Health care workers at risk of PTSD from COVID: guide

Doctors say experimental treatment may have rid man of HIV

Doctors say experimental treatment may have rid man of HIV
A Brazilian man infected with the AIDS virus has shown no sign of it for more than a year since he stopped HIV medicines after an intense experimental drug therapy aimed at purging hidden, dormant virus from his body, doctors reported Tuesday.

Doctors say experimental treatment may have rid man of HIV

AIDS report: Kids are lagging and COVID-19 is harming care

AIDS report: Kids are lagging and COVID-19 is harming care
New numbers on the global AIDS epidemic show some big successes, such as fewer deaths and new infections. But there are also some tragic failures: Only half the children with HIV, the virus that causes the disease, are getting treatment.

AIDS report: Kids are lagging and COVID-19 is harming care

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19
Dr. Bal Pawa is a uniquely qualified pharmacist and medical doctor. The combined knowledge, plus 3 decades of clinical experience have fuelled her passion to change the way medical care is delivered

Dr.Bal Pawa shares information on how to tackle mental health challenges amidst COVID-19

Gilead's $2,340 price for coronavirus drug draws criticism

Gilead's $2,340 price for coronavirus drug draws criticism
The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead's $2,340 price for coronavirus drug draws criticism